BIOVERATIV INC Dirigenti
| Dirigenti | Titolo | Età | Da |
|---|---|---|---|
William Sibold
PSD | President | 57 | 08/03/18 |
Joann Nestor
SEC | Corporate Secretary | - | - |
| Corporate Officer/Principal | - | - | |
Timothy Harris
PRN | Corporate Officer/Principal | 74 | 01/02/17 |
Amministratori
| Amministratori | Titolo | Età | Da |
|---|---|---|---|
William Sibold
PSD | President | 57 | 08/03/18 |
Philippe Sauvage
BRD | Director/Board Member | - | 08/03/18 |
Classe di azioni
| Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
|---|---|---|---|---|---|
| Azione A | 1 | 108 223 644 | 107 993 510 ( 99,79 %) | 0 | 99,79 % |
Coordinate società
Società del gruppo
| Nome | Categoria e settore |
|---|---|
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Settore
| Variaz. 1 gen. | Capi. | |
|---|---|---|
| +20,12% | 127 Mrd | |
| +25,25% | 117 Mrd | |
| +25,56% | 27,77 Mrd | |
| -19,51% | 20,44 Mrd | |
| -14,36% | 16,62 Mrd | |
| -15,63% | 15,92 Mrd | |
| -46,67% | 14,94 Mrd | |
| +11,89% | 14,74 Mrd | |
| +57,74% | 14,38 Mrd |
